Cytokine Hemadsorption in Covid 19 Patients With Bacterial Sepsis

• Conditions: INTERLEUKIN 6

• Registration Number: NCT04920851
• Lead Sponsor: Derince Training and Research Hospital

Brief Summary

In this retrospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-06
• Study First Submitted: 2021-06-09
• Study First Submitted QC: 2021-06-09
• Last Update Submitted: 2021-06-09
• Study Start: 2021-06-10
• Study First Posted: 2021-06-10
• Last Update Posted: 2021-06-10
• Primary Completion: 2021-07-05
• Study Completion: 2021-07-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• COVID-19 patients were the available data of laboratory diagnosis of COVID-19 (a positive throat swab nucleic acid test or positive serum COVID-19 specific antibody test),
• patients with COVID-19 induced sepsis was detection of bacterial agent in blood or tracheal culture

Exclusion Criteria

• below 18 aged
• those who did not undergo hemoperfusion

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
interleukin 6	1 month	level of interleukin 6

Trial Locations

Locations (1)

Biruni University; 🇹🇷 Istanbul, Küçükçekmece, Turkey